184 related articles for article (PubMed ID: 23681113)
1. Specific lymph node involvement in scleromyxedema: a new diagnostic entity for hypermetabolic lymphadenopathy.
Delyon J; Bézier M; Rybojad M; Brière J; Validire P; Bagot M; Janin A; Battistella M
Virchows Arch; 2013 Jun; 462(6):679-83. PubMed ID: 23681113
[TBL] [Abstract][Full Text] [Related]
2. Managing scleromyxedema with intravenous immunoglobulin: acute worsening of scleromyxedema with biclonal gammopathy.
Manousaridis I; Loeser C; Goerdt S; Hassel JC
Acta Dermatovenerol Alp Pannonica Adriat; 2010 Dec; 19(4):15-9. PubMed ID: 21390475
[TBL] [Abstract][Full Text] [Related]
3. Scleromyxedema with an interstitial granulomatous-like pattern: a rare histologic variant mimicking granuloma annulare.
Rongioletti F; Cozzani E; Parodi A
J Cutan Pathol; 2010 Oct; 37(10):1084-7. PubMed ID: 19638067
[TBL] [Abstract][Full Text] [Related]
4. Scleromyxedema Without Monoclonal Gammopathy Treated with Intravenous Immunoglobulins.
Letzelter M; Grimaux X
Acta Dermatovenerol Croat; 2021 Apr; 291(1):51-53. PubMed ID: 34477065
[TBL] [Abstract][Full Text] [Related]
5. [Monoclonal immunoglobulin (M-Ig) and skin diseases from the group of mucinoses--scleredema adultorum Buschke and scleromyxedema. Description of four cases and an overview of therapies].
Adam Z; Szturz P; Krejčí M; Vašků V; Pour L; Michalková E; Ševčíková S; Čermáková Z; Veselý K; Vaníček J; Pourová E; Král Z; Mayer J
Vnitr Lek; 2015 Dec; 61(12):1072-87. PubMed ID: 26806503
[TBL] [Abstract][Full Text] [Related]
6. Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.
Mahévas T; Arnulf B; Bouaziz JD; Livideanu CB; Osio A; Servy A; Cribier B; Sassolas B; Jachiet M; Michel L; Aucouturier P; Lipsker D; Frances C; Sbidian E; Rybojad M; Descamps V; D'Incan M; Humbert P; Beylot-Barry M; Passeron T; de Moreuil C; Taha RY; Hermine O; Dupuy A; Barbarot S; Debarbieux S; Carpentier O; Brault F; Schmutz JL; Thomas-Beaulieu D; Modiano P; Zarnitsky C; Lifermann F; Baubion E; Limal N; Le Bras F; Le Moigne M; Tauber M; Talbot A; Prud'homme R; Peltier S; De Masson A; Battistella M; Bagot M; Mékinian A; Fain O
Blood; 2020 Apr; 135(14):1101-1110. PubMed ID: 32027747
[TBL] [Abstract][Full Text] [Related]
7. Scleromyxedema with multiple systemic involvement: Successful treatment with intravenous immunoglobulin.
Kim S; Park TH; Lee SM; Kim YH; Cho MK; Whang KU; Kim HS
Dermatol Ther; 2020 May; 33(3):e13378. PubMed ID: 32250023
[TBL] [Abstract][Full Text] [Related]
8. Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins.
Wang SS; Chen QY; Xiang LH
Front Immunol; 2022; 13():1099918. PubMed ID: 36713453
[TBL] [Abstract][Full Text] [Related]
9. Acute Encephalitic Syndrome Induced by Scleromyxedema.
Magira EE; Malouchou A; Karathanasi V; Mavropoulou N; Siempos II; Vourlakou C; Sykaras A; Anastasiadis G
Am J Med Sci; 2020 Aug; 360(2):192-195. PubMed ID: 32540147
[TBL] [Abstract][Full Text] [Related]
10. Scleromyxedema in a 21 year old female patient with acute lymphoblastic leukemia: a case report.
Rabee H; Tayem L; Gharbeyah M; Abugaber D
BMC Dermatol; 2020 Dec; 20(1):18. PubMed ID: 33276772
[TBL] [Abstract][Full Text] [Related]
11. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients.
Rongioletti F; Merlo G; Cinotti E; Fausti V; Cozzani E; Cribier B; Metze D; Calonje E; Kanitakis J; Kempf W; Stefanato CM; Marinho E; Parodi A
J Am Acad Dermatol; 2013 Jul; 69(1):66-72. PubMed ID: 23453242
[TBL] [Abstract][Full Text] [Related]
12. An unusual presentation of scleromyxedema as inflammatory myopathy.
Vysakha KV; Poyuran R; Nair SS; Nair M
Acta Myol; 2019 Mar; 38(1):13-16. PubMed ID: 31309176
[TBL] [Abstract][Full Text] [Related]
13. Resident Rounds part III: scleromyxedema: a rare disorder associated with a monoclonal gammopathy.
Mandell JA; Glick JB; Kaur RR
J Drugs Dermatol; 2014 May; 13(5):619-20. PubMed ID: 24809891
[TBL] [Abstract][Full Text] [Related]
14. Myopathy and scleromyxedema.
Soulages A; Tang HM; Pham-Ledard A; Négrier-Leibreich ML; Cosnard A; Duval F; Solé G; Carla L; Le Masson G; Mathis S
J Neurol; 2019 Aug; 266(8):2051-2059. PubMed ID: 31115676
[TBL] [Abstract][Full Text] [Related]
15. Scleromyxedema with monoclonal gammopathy and neurological involvement: recovery from coma after plasmapheresis?
do Prado AD; Schmoeller D; Bisi MC; Piovesan DM; Dias FS; Staub HL
Int J Dermatol; 2012 Aug; 51(8):1013-5. PubMed ID: 21671910
[No Abstract] [Full Text] [Related]
16. [Marked improvement in scleromyxedema with high-dose intravenous immunoglobulin].
Topf S; Simon M; Schell H; Lüftl M
Hautarzt; 2007 Jun; 58(6):525-8. PubMed ID: 17165069
[TBL] [Abstract][Full Text] [Related]
17. [Clinical characteristics, outcome of scleromyxoedema: a retrospective multicentre study].
Le Moigne M; Mazereeuw-Hautier J; Bonnetblanc JM; Astudillo L; D'Incan M; Bessis D; Thomas L; Debarbieux S; Ammoury A; Lamant L; Paul C
Ann Dermatol Venereol; 2010 Dec; 137(12):782-8. PubMed ID: 21134580
[TBL] [Abstract][Full Text] [Related]
18. [Response to thalidomide in scleromyxedema].
Pascualini MF; Caballero Escuti G; Valente E; Kurpis M; Ruiz Lascano A
Medicina (B Aires); 2013; 73(3):252-4. PubMed ID: 23732202
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal IgG kappa gammopathy previous to hematopoietic stem cell transplantation in an infant with severe combined immunodeficiency.
Simão I; Cordeiro AI; Borrego LM; Martins C; Neves C; Neves JF
Clin Immunol; 2012 Nov; 145(2):133-5. PubMed ID: 23022654
[No Abstract] [Full Text] [Related]
20. Characterization of circulating myeloma tumor cells by next generation flowcytometry in scleromyxedema patient: a case report.
Taha RY; Hasan S; Ibrahim F; Chantran Y; Sabah HE; Sivaraman S; Bozom IA; Sabbagh AA; Garderet L; Omri HE
Medicine (Baltimore); 2020 Jul; 99(27):e20726. PubMed ID: 32629647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
